Clinical Trials Logo

Hepatitis C clinical trials

View clinical trials related to Hepatitis C.

Filter by:

NCT ID: NCT03212521 Completed - Clinical trials for Hepatitis C Virus (HCV)

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Start date: August 7, 2017
Phase: Phase 3
Study type: Interventional

A study to evaluate the efficacy and safety of glecaprevir(GLE)/pibrentasvir(PIB) in treatment-naïve participants with chronic hepatitis C virus (HCV) genotypes 1-6 infection and with an aspartate aminotransferase to platelet ratio index (APRI) of less than or equal to 1.

NCT ID: NCT03208322 Withdrawn - Hepatitis C Clinical Trials

Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults

Start date: November 30, 2018
Phase:
Study type: Observational

The primary objective of the study is to determine the number of adverse events (AEs) reported by chronic hepatitis C (CHC) patients receiving at least 1 dose of daclatasvir (DCV) and asunaprevir (ASV) at the 2 sentinel sites and that have been reported through the Mexican Health Authority's AE surveillance system during a specified 24-month study period. The secondary objective is to describe AEs reported by CHC patients receiving treatment with DCV and ASV treated by doctors at participating sentinel sites for the National Pharmacovigilance Center (CNFV) in Mexico during a specified 24-month study period.

NCT ID: NCT03208244 Terminated - Hepatitis C Clinical Trials

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant

Start date: November 9, 2017
Phase: Phase 4
Study type: Interventional

This is a proof of concept, single center study for the donation of HCV-positive hearts to HCV negative recipient patients, with preemptive, interventional treatment with 12 weeks of commercially available DAA therapy to prevent HCV transmission upon transplantation.

NCT ID: NCT03208127 Terminated - Hepatitis C Clinical Trials

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

Start date: November 21, 2017
Phase: Phase 4
Study type: Interventional

This is a single center study for the donation of Hepatitis C Virus (HCV)-positive livers to HCV negative recipient patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.

NCT ID: NCT03207399 Terminated - Clinical trials for Hepatitis C, Chronic

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

Start date: September 15, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate whether treatment with Epclusa (sofosbuvir/velpatasvir) after lung transplantation in individuals with chronic hepatitis C infection is feasible, safe and effective at curing HCV.

NCT ID: NCT03205618 Completed - Hepatitis C Clinical Trials

A Retrospective, Observational Study on the Effectiveness of Daclatasvir-Containing Regimens in Patients in KSA, UAE and Qatar

Start date: April 26, 2016
Phase: N/A
Study type: Observational

The study will provide safety and efficacy information among patients receiving daclatasvir. It will describe daclatasvir prescribing patterns and provide a clinical profile of patients receiving the treatment in KSA, UAE, and Qatar.

NCT ID: NCT03201718 Completed - Clinical trials for Hepatitis C Virus (HCV)

A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs

HCV PMS
Start date: August 17, 2017
Phase:
Study type: Observational

Post-marketing surveillance study to evaluate the real world safety and effectiveness of Viekira/ Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) administered under a normal, routine treatment practice by Korean patients with Hepatitis C.

NCT ID: NCT03200379 Recruiting - Clinical trials for Hepatitis C, Chronic

Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan

Start date: June 15, 2017
Phase:
Study type: Observational

To determine the treatment efficacy, safety and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals in Taiwan

NCT ID: NCT03200184 Completed - Hepatitis C Clinical Trials

Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients

SD1000
Start date: September 1, 2016
Phase: Phase 4
Study type: Interventional

The fixed-dose combination of sofosbuvir and daclatasvir in a single pill is being used for the treatment of hepatitis C in Iran. In this study the efficacy of this combination is evaluated in 1000 patient with hepatitis C.

NCT ID: NCT03200171 Completed - Hepatitis C Clinical Trials

Effect of DAAs on Behavior of HCC in HCV Patients

Start date: February 10, 2018
Phase:
Study type: Observational

Investigators aim to study the effect of direct acting antiviral agents (DAAs) on behavior of hepatocellular carcinoma (HCC) and overall survival in patients with chronic hepatitis C (CHC).